ImmunoBrain Checkpoint Information

View Top Employees from ImmunoBrain Checkpoint

ImmunoBrain Checkpoint (IBC) is a clinical stage biopharmaceutical company transforming the fight against neurodegeneration and aging by targeting the immune system, restoring brain immune communications and boosting natural repair mechanisms. IBC’s lead program is a proprietary antibody targeting the inhibitory immune checkpoint pathway PD-1/PD-L1, to treat Alzheimer's disease. IBC's novel approach for the treatment of neurodegeneration is based on years of innovative, cutting-edge scientific discoveries made in the lab of Prof. Michal Schwartz at the Weizmann Institute of Science.

Website	https://www.immunobrain.com/
Revenue	$3 million
Employees	19 (0 on RocketReach)
Founded	2015
Technologies	JavaScript , HTML , PHP +14 more (view full list)
Industry	Biotechnology Research, Business Services General, Biotechnology, Business Services, Science and Engineering, Pharmaceutical, Health Care
Keywords	Immune System, Immunotherapy, Immune Modulation, Neurological Disorders, Brain Health, Aging, Brain Repair, Alzheimers, Parkinsons, Therapeutic Antibodies, Biopharmaceutical, Clinical Trials, Regenerative Medicine, Precision Medicine, Clinical Stage, Drug Development, Biotechnology
Competitors	Novartis, Merck & Co., Inc., Pfizer, Bristol Myers Squibb, Amgen, Biogen, Neurocrine Biosciences, Omeros Corporation, Lilly India, Axovant Sciences Ltd +44 more (view full list)
SIC	SIC Code 87 Companies, SIC Code 873 Companies, SIC Code 80 Companies, SIC Code 28 Companies, SIC Code 283 Companies
NAICS	NAICS Code 54 Companies, NAICS Code 5417 Companies, NAICS Code 541711 Companies, NAICS Code 541 Companies, NAICS Code 54171 Companies